Rare lephants
Screener

Cytosorbents Corporation

CTSO ·Healthcare, Medical Devices, United States
Valuation › AI Valuation

AI Valuation

AI-generated fair value estimate for this company.

AI Fair Value $3.87
Market Price $3.85
Undervalued By 0.5%

Method: EV/Revenue cross-check: $37.22M TTM revenue at a conservative 1.0x multiple (reflecting the company's 71.6% gross margin but ongoing cash-burn and leverage) = $37.22M EV; less $25.02M net debt = $12.2M equity value / 3.15M shares = $3.87/share.

Reasoning: CytoSorbents carries meaningful debt ($29.4M) against only $4.4M of cash and negative operating cash flow, so a standard owner-FCF DCF produces a nonsensical negative equity value; an EV/Revenue multiple anchored to the company's high gross margin and FDA-cleared blood-purification product line is a more appropriate rigorous method for this leveraged, pre-profitability medtech.